In a patient with p‑ANCA‑positive, MPO/PR3‑negative small‑vessel vasculitis and impaired renal function (creatinine ~2 mg/dL), should high‑dose glucocorticoids be started now or wait until after the kidney biopsy?

Should Steroids Be Started Before or After Kidney Biopsy in p-ANCA+ Small-Vessel Vasculitis?

Start high-dose glucocorticoids immediately without waiting for kidney biopsy in this patient with clinical presentation compatible with ANCA-associated vasculitis, positive p-ANCA serology, and rapidly deteriorating renal function (creatinine ~2 mg/dL). 1, 2

Rationale for Immediate Treatment

The 2024 KDIGO guideline explicitly states that in patients with clinical presentation compatible with small-vessel vasculitis combined with positive MPO- or PR3-ANCA serology, waiting for kidney biopsy to be performed or reported should not delay starting immunosuppressive therapy, especially in patients who are rapidly deteriorating. 2

• This practice point was reinforced in the 2023 KDOQI US Commentary, emphasizing the urgency in treating ANCA-associated glomerulonephritis because it often presents as rapidly progressive glomerulonephritis (RPGN), and timely initiation of immunosuppressive therapy is of utmost importance to swiftly control inflammation and preserve nephron function. 1

• The combined presence of a clinical presentation compatible with small vessel vasculitis and a positive MPO/PR3 ANCA serology is sufficient to begin immunosuppressive therapy while awaiting kidney biopsy to be performed or reported. 1

Timing Strategy

Begin treatment immediately, then perform kidney biopsy soon after starting treatment when feasible. 2, 3

• The 2024 KDIGO guideline provides a clear algorithm: in experienced centers with rapidly progressive disease and positive PR3- or MPO-ANCA, commence treatment first, then biopsy soon after starting treatment when feasible. 2

• While kidney biopsy remains the gold standard with diagnostic and prognostic value in AAV, it should not delay therapy initiation. 1

Initial Treatment Regimen

Start high-dose glucocorticoids in combination with either rituximab or cyclophosphamide (Grade 1B). 2

• For patients with markedly reduced or rapidly declining GFR (serum creatinine >4 mg/dL [>354 μmol/L]), there are limited data to support rituximab and glucocorticoids alone; both cyclophosphamide and glucocorticoids, or the combination of rituximab and cyclophosphamide can be considered. 2

• Your patient with creatinine ~2 mg/dL falls below this severe threshold, so either rituximab or cyclophosphamide with glucocorticoids is appropriate. 2

• The 2009 EULAR recommendations support high-dose glucocorticoids as an important part of remission induction therapy, commonly commencing prednisolone at 1 mg/kg/day, maintained for 1 month, and not reduced to less than 15 mg/day for the first 3 months. 4

Critical Caveat: Exclude Infection First

The only absolute requirement before starting immunosuppression is excluding infection with as much certainty as possible. 3

• Infection must be excluded before significant immunosuppression is given, as this is the primary safety consideration that could justify delaying treatment. 3

• Once infection is reasonably excluded, treatment should proceed immediately without waiting for biopsy results. 1, 2

Why Biopsy Still Matters (But Later)

Perform kidney biopsy as soon as feasible after starting treatment because it provides crucial prognostic information and confirms diagnosis, even though it should not delay therapy. 1, 2

• Kidney biopsy helps distinguish ANCA-associated vasculitis from other causes of RPGN (anti-GBM disease, lupus nephritis) and provides prognostic information about chronicity and potential for recovery. 1, 3

• The biopsy can be safely performed shortly after initiating steroids without significantly compromising diagnostic yield. 2

Common Pitfalls to Avoid

• Do not wait for biopsy results to start treatment in a patient with compatible clinical presentation and positive ANCA serology, as renal recovery is strongly tied to early diagnosis and prompt institution of therapy. 1, 5

• Do not assume you need histologic confirmation before treating when you have both clinical compatibility and positive serology—this combination is sufficient. 1, 2

• Do not delay treatment to "rule out" other diagnoses if the clinical picture and serology point to ANCA vasculitis; the risk of irreversible nephron loss from delayed treatment far exceeds the risk of treating empirically. 1, 2

• Do not forget that your patient is p-ANCA positive but MPO/PR3 negative—this is unusual and warrants consideration of drug-induced vasculitis (hydralazine, propylthiouracil, levamisole-adulterated cocaine) or other ANCA-negative vasculitis, but should still not delay empiric treatment given the clinical presentation. 1